CD38, a transmembrane glycoprotein upregulated on MM cells, represents an attractive target for immunotherapies and has encouraged the development of anti-CD38 mAbs, i.e., daratumumab, isatuximab, and MOR202 [86]. Here, CD38 is linked to Miyoshi myopathy.